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QUESTION ASKED: What strategies do US cancer
centers use to optimize recruitment of racial and
ethnic minority groups (REMGs) into clinical trials?
SUMMARY ANSWER: Strategies that drive increased
participation of REMGs in cancer clinical trials were
identiﬁed across ﬁve broad themes—commitment and
center leadership, investigator training and mentoring,
community engagement, patient engagement, and
operational practices. Speciﬁc notable practices included the following: increased engagement of health
care professionals; presence of formal processes for
obtaining REMG patient/caregiver input on research
projects; engagement of community groups; an increase in allocation of resources to improving health
disparities; and increased dedication of research staff
to REMG engagement.
WHAT WE DID: In-depth interviews were conducted
with leaders from US cancer centers with aboveaverage recruitment of REMGs into clinical trials to
identify speciﬁc strategies that were used to facilitate
REMG participation.

WHAT WE FOUND: We identiﬁed leadership, patient
engagement, and community engagement practices that
facilitate increased accrual of REMGs in cancer trials. In
particular, high-recruiting centers excelled in engaging
with providers as the most important inﬂuencer of patient
participation, engaging community leaders and building
trust, and seeking dedicated input clinical research
programs from REMG patients and caregivers to identify
and overcome potential barriers as early as possible.
BIAS, CONFOUNDING FACTOR(S): The small sample
size, type of cancer center included in the study, and
the lack of comparison group could have affected the
interpretation of the results.
REAL-LIFE IMPLICATIONS: Increased participation of
REMGs in cancer research is needed to ensure that
medicines developed for and administered to patients with
cancer demonstrate their intended beneﬁt in clinical trials
that adequately represent the diversity of the US population. Practicing oncologists can help to ensure that all
patients can beneﬁt from the newer, increasingly personalized therapies by adopting identiﬁed notable practices that increase recruitment of REMGs into clinical trials.
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abstract

PURPOSE Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproportionately low
despite a high prevalence of certain cancers in REMG populations. We aimed to identify notable practices used
by leading US cancer centers that facilitate REMG participation in cancer trials.
METHODS The National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group developed criteria by which to identify eligible US cancer centers—REMGs comprise
10% or more of the catchment area; a 10% to 50% yearly accrual rate of REMGs in cancer trials; and the
presence of formal community outreach and diversity enrollment programs. Cancer center leaders were
interviewed to ascertain notable practices that facilitate REMG accrual in clinical trials.
RESULTS Eight cancer centers that met the Communities Working Group criteria were invited to participate in indepth interviews. Notable strategies for increased REMG accrual to cancer trials were reported across ﬁve broad
themes: commitment and center leadership, investigator training and mentoring, community engagement, patient
engagement, and operational practices. Speciﬁc notable practices included increased engagement of health care
professionals, the presence of formal processes for obtaining REMG patient/caregiver input on research projects, and
engagement of community groups to drive REMG participation. Centers also reported an increase in the allocation of
resources to improving health disparities and increased dedication of research staff to REMG engagement.
CONCLUSION We have identiﬁed notable practices that facilitate increased participation of REMGs in cancer
trials. Wide implementation of such strategies across cancer centers is essential to ensure that all populations
beneﬁt from advances in an era of increasingly personalized treatment of cancer.
J Oncol Pract 15:e289-e299. © 2019 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
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Diverse patient populations in the United States are
regularly underrepresented in clinical trials, which
stand as the ﬁrst portal to standard of care and innovative care. Whereas less than 10% of patients with
cancer participate in US cancer clinical trials, participation of racial and ethnic minority groups (REMGs)
is disproportionately low. 1 For example, African
American patients comprise 5% of patients enrolled in
clinical trials that support US Food and Drug Administration approval of new drugs but represent
13.3% of the general US population.2 Cancer is the
leading cause of death for Asian Americans,3 yet
this population comprises 3% of cancer clinical trial
participants.4 Hispanics are also similarly underrepresented in clinical trials.5 These health inequities are

increasingly untenable, with advances in science and
technology driving a paradigm shift with precision
medicine, especially in cancer.
Without opportunities to participate in clinical trials,
REMGs miss the chance to participate in clinical trials
that are often standard in oncology practice and are
not being included in the populations assessed for
safety and efﬁcacy of innovative therapies. Delivering
personalized medicines that account for biologic
factors, such as genetics, gender, race, and ethnicity,
is fundamental to the goal of precision medicine;
however, without including adequate representative
patient populations, this goal is not achievable.6-8
Continued focus on increased participation of REMGs
in cancer research is needed to improve our understanding of differences in risk and disease outcomes
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across populations. This work describes a data-driven strategy
with which to identify and document notable leadership
standards and patient- and community-centered practices
that characterize US Centers’ of Excellence ability to achieve
above-average accrual of REMGs in cancer clinical research.
We describe the development of and results from an extensive
qualitative and quantitative data assessment conducted by
the Sustainable Healthy Communities Diverse Cancer Communities Working Group (CWG) to share best practices and a
framework supportive for enhancing REMG participation and
inclusion in US cancer research.
METHODS
The CWG applied criteria (Table 1) that was developed by a
focus group of 14 US diversity thought leaders to identify
potential US cancer centers of excellence. A cohort of
cancer centers that met CWG criteria were invited to share
their practices. The CWG conducted a literature review to
inform data collection research methodology (Fig 1). Preand postinterview surveys and an interview guide were
developed to standardize data collection. Surveys were sent
to participating cancer centers within 2 weeks of a
scheduled interview. The discussion guide included openended questions and was used to capture notable practices. The preinterview survey was reviewed in advance of
the interview and provided preliminary information that
informed the interview. The postinterview survey collected
additional clarifying information upon completion and review of the interview. When interviewed, center leaders
validated the content of the two survey instruments and
discussion guide as being complete for the patient. The
discussion guide focused on capturing notable practices
covering six major themes: leadership and commitment,
operational capabilities, community engagement, patient
engagement, investigator training and hiring/mentoring,
and recommended sponsor practices for enhanced
REMG recruitment. Pre- and postinterview surveys were
used to conﬁrm participation eligibility, align on key deﬁnitions, and explore emergent themes using consistent
deﬁnitions (Data Supplement). The preinterview survey,

discussion guide, and postinterview survey are provided in
the Data Supplement. Interview notes, provided as a
summary document, were sent to each of the center’s
leaders to validate the accuracy of responses before aggregation of data and notable practices. A single experienced
interviewer conducted all interviews and administered all
surveys, which were completed between November 2017
and February 2018.
RESULTS
On the basis of the methods described previously, the CWG
selected the following cancer centers: Fox Chase Cancer
Center/Temple Health (FCCC; Philadelphia, PA); the
Harold C. Simmons Comprehensive Cancer Center/
University of Texas Southwestern (Dallas, TX); the Henry
Ford Cancer Institute (HFCI; Detroit, MI); the Hollings
Cancer Center/Medical University of South Carolina
(MUSC; Charleston, SC); the John T. Vucurevich Cancer
Institute/Rapid City Regional Hospital (JVCI; Rapid City,
SD); The University of Texas MD Anderson Cancer Center
(MDACC; Houston, TX); the University of California Davis
Comprehensive Cancer Center (UCDCCC; Sacramento,
CA); and the Winship Cancer Institute of Emory University
(WCI-EMORY; Atlanta, GA). All centers included in the
assessment met all criteria for inclusion and represented
every major ethnic minority group according to the Health
and Human Services, Ofﬁce of Management and Budget
race and ethnicity designations.11 All centers targeted
populations that were consistent with their catchment or
service area. Overall, 14 leaders representing eight cancer
centers participated in this assessment. Every leader in
each of the eight centers participated throughout the assessment. Interviewees were nominated by center leaders
according to their expertise relative to the objectives of the
assessment, and results were not variable on the basis of
the role or function of leaders included in the assessment.
Summary of Results From Quantitative Surveys
In a 12-month reporting period between 2016 and 2018,
centers reported a speciﬁc 10% range of accrual and

TABLE 1. Cancer Center Selection Criteria
Criteria
Sustained accrual of racial and ethnic minorities in all cancer clinical research of between 10% and 50%
Established minority population $ 10% of the total site catchment, as conﬁrmed by Sustainable Healthy Communities Cancer Index9
Established clinical trial infrastructure,10 reﬂecting consistent industry clinical trial operations standards for clinical trial sites
Data infrastructure10 or previous positive US Food and Drug Administration audit
Provider language and cultural competency reﬂects demographics of the populations they serve
Existing diversity enrollment program for clinical trials*
Formal community outreach program
Ability to participate in biomarker and metabolism research (eg, tissue correlative laboratories or pharmacokinetics capability)
*The CWG deﬁned an existing diversity enrollment program as a center having people and processes dedicated to optimizing the goal of
diversity and inclusion in cancer clinical trials.
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A focus group of diversity thought leaders identified criteria (Table 1) for the identification of potential
US cancer centers of excellence to compare the practices of similar cancer centers.

A standard invitation template was sent via email to the cancer center leadership of US cancer centers
meeting criteria by the CWG chairperson. CWG prepared a standard preinterview survey and discussion
guide with themes and objectives of the survey. These were included in the invitation to the cancer center
leader to inform their identification and nomination of relevant participants for the assessment.

CWG identified and invited 10 US cancer centers who met all eight selection criteria to
participate in the assessment.

Two center leaders did not respond to
the CWG invitation and were not
included in the assessment.

Eight of 10 invited center leaders responded to the CWG invitation and nominated 14 leaders
to participate in the assessment. Preinterview surveys and discussion guides were sent
to all nominated participants ahead of interviews.

One experienced interviewer conducted 1-hour phone interviews using the discussion guide with one to two
participants from each center on individual or group cancer center calls.

FIG 1. Research methodology ﬂow
diagram. CWG, Sustainable Healthy
Communities Diverse Cancer Communities Working Group.

Preinterview survey responses, key practices by theme, examples, and references were captured and
recorded in a consistent template as a summary document for approval by each participant.

CWG reviewed initial survey responses to identify emergent themes and areas requiring additional
information from participants. CWG prepared a standard postinterview survey covering
the additional information required, which was sent to all participants completed and collated
within each center and returned for analysis.

Summary documents incorporating preinterview and postinterview survey responses and discussion
summaries for each cancer center were prepared by the interviewer and approved by
participants at each center.

Cancer center documents were aggregated by practice theme and subject by the interviewer.
Quantitative and qualitative survey questions and associated responses were extracted
from both surveys for reporting purposes.

reported targeted programs for REMGs in their cancer
clinical trials. All centers targeted populations that were
consistent with their catchment or service area: FCCC, 10%
to 20% (African Americans, Hispanic Americans, Asian
Americans); University of Texas Southwestern, 30% to
40% (African Americans, Hispanic Americans); HFCI, 30%
to 40% (African Americans); MUSC, 20% to 30% (African
Americans, Hispanic Americans); JVCI, 10% to 20%
(American Indians/Alaskan Natives); MDACC, 10% to 20%
(African Americans, Hispanic Americans, Asian Americans); UCDCCC, 30% to 40% (Asian Americans); and WCIEMORY, 20% to 30% (African Americans, Hispanic

Americans). Overall, the reported percentage of REMG
participants accrued in cancer clinical trials for all eight
cancer centers ranged from 10% to 40% in this time period. The majority (six of eight centers) used National
Cancer Institute grant criteria12 as a metric scorecard for
inclusion of REMGs and captured Ofﬁce of Minority Health
data in the clinical trial database (seven centers and one
center unknown degree of capture). Ofﬁce of Minority
Health REMG data were reported by the patient directly
(four centers), research staff informed by direct patient
query (two centers), or research staff on the basis of visual
observation (one center), and one center’s reporting varied
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by trial. All centers captured REMG data in written format
and six centers also had Web-based capture.
Summary of Results From Qualitative Surveys
Qualitative surveys conducted in each center identiﬁed
center-reported outcomes and success factors for REMG
recruitment in cancer research. All centers reported that
the proportion of REMGs included in cancer research and
the engagement of health care professionals in the community as partners had increased over time. Centers also
reported the establishment of a process for obtaining
ethnically diverse patients’ and/or caregivers’ input on research projects, as well as engagement of community
groups to drive REMG participation. The majority (seven
centers) also reported an increase in research funds allocated to understanding, addressing, and improving
health disparities, and increased dedication of research
center staff to REMG engagement (six centers) over the
time period. Five centers reported that community-based
participatory research strategies are used as a measure of
progress to engage REMGs.
Notable Practices Summary
The qualitative survey identiﬁed notable practices across
ﬁve themes: commitment and center leadership, investigator training and mentoring practices, community
engagement, patient engagement, and operational practices, which are listed in Table 2.
Leadership and Commitment
Commitment from cancer center leadership toward an
institutional focus on diversity and physician and patient
engagement results in enhanced inclusion of REMGs in
cancer clinical research. Health systems and cancer
centers that prioritized recruitment of a diverse faculty
demonstrated a commitment to health equity. Six of eight
centers reported having a standing cancer center leadership advisory committee that focuses on various aspects
including, but not limited to, metrics, process improvement,
and notable practices. Three centers reported having
leadership support for system-wide campaigns and programs that focus on education and the importance of research and collaboration. MUSC leadership noted the
expansion of a state-wide program to reduce cancer
disparities.
High REMG recruiting cancer centers model inclusive institutional culture by establishing leadership roles dedicated to diversity issues and minority faculty recruitment.
Centers that promote partnerships between faculty and
community physicians streamlined access to clinical
studies. For example, 30% to 40% of HFCI trial participants
were REMGs enrolled through partner research sites.
Broad leadership commitment to inclusive patient engagement and outreach to increase the visibility of trials
was noted as being key to increasing access and
enrollment.

Investigator Hiring, Training, and Mentoring Practices
Leaders consistently reported a longstanding organizational
commitment to quality and diversity in hiring practices,
development, and cultural training. Center leaders (HFCI)
noted that hiring of research staff that is reﬂective of the
catchment area provides an opportunity to learn and
achieve innovative practices. In addition, center leaders
(MDACC and WCI-EMORY) noted the importance of developing a diverse faculty reﬂective of their catchment area
and creating an inclusive institutional culture for women
and REMGs.
Seven of eight cancer centers noted programs in which
junior faculty or students are trained or mentored by senior
faculty on aspects of cultural competency and an effective
clinical trial discussion approach with patients and care
partners. At UCDCCC, senior faculty mentor junior faculty to
conduct and generate publications in health disparities
research.
Community Engagement Practices
Having an institutional presence in the community
emerged as a fundamental requirement for increasing
visibility and developing trustful working relationships with
potential research partners. Centers noted the need to
invest time and effort with key community representatives
to learn about the community, its needs, and potential
facilitators and barriers to research participation before
approaching communities about research. This upfront
investment also enabled researchers to better prepare and
engage other relevant staff, such as navigators and ﬁnancial counselors. Leaders noted that authentic partnerships with communities must extend beyond individual
research projects, and that the provision of additional related services is also necessary to build capacity. These
services could include multilingual cancer education, describing how research contributes to better care and survivorship as well as access to screening and other
preventive health services.
Speciﬁc strategies used by multiple institutions to enhance
community outreach and engagement included the
following:

• Cultural competence training for staff that includes
information about motivators, challenges, and barriers
to research participation among REMGs
• Community advisory boards composed of diverse
stakeholders to guide the development, feasibility, and
implementation of research studies
• Lay community representatives—ambassadors—from
REMG communities to cultivate community talent and
tap into their expertise and networks to reach potential
research participants
• Transparency in sharing research ﬁndings, potentially
via concise, plain language summaries to help participants understand their contributions to science and
their community
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Abbreviations: AI, American Indian; CAPACHE, Comprehensive Partnerships to Advance Cancer Health Equity; FCCC, Fox Chase Cancer Center/Temple Health; HCC, hepatocellular carcinoma; HCP,
health care provider; HFCI, Henry Ford Cancer Institute; JVCI, John T. Vucurevich Cancer Institute/Rapid City Regional Hospital; MDACC, MD Anderson Cancer Center; MUSC, Hollings Cancer Center/
Medical University of South Carolina; REMG, racial and ethnic minority group; UCDCCC, University of California Davis Comprehensive Cancer Center; UTSW, Harold C. Simmons Comprehensive Cancer
Center/University of Texas Southwestern; WCI-EMORY, Winship Cancer Institute/Emory.
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Using these strategies was reported as a means to enhance
recruitment efforts and to strengthen community partnerships, often described as trusted brokers, with patients and
care partners. Although community education and outreach can increase a community’s understanding of
research, leaders noted that the actual invitation to participate in a speciﬁc study must remain in the hands of an
investigator or study coordinator involved in the study—and
in the case of an intervention treatment study, ideally the
physician caring for the patient.
Patient Engagement Practices
Leaders noted that a provider’s recommendation is the
most important factor that inﬂuences a patients’ willingness
to participate in clinical research. The provider is ultimately
responsible for discussing with the patient their potential
eligibility for a speciﬁc clinical trial at the time patients make
decisions on treatment as part of holistic discussions on the
current standard of care and the most appropriate treatment approach.
Three additional notable practices reported by all centers
included engaging the patient in trial participation decision
making; ensuring the availability of culturally appropriate,
ethnicity-speciﬁc, and cognitively empowering materials;
and earning the trust of the patient.
According to the leaders, for patients to make an informed
decision regarding the choice to participate in clinical research, study materials (for example, educational pamphlets) must be both culturally and linguistically accessible
and user friendly. This includes information produced in
various formats (for example, print, audio, or video) and in
common and lesser-known languages of REMG communities. Furthermore, leaders noted that patients are more
likely to engage in clinical research if providers and researchers take the time to build trusting relationships with
patients and their families.
DISCUSSION
Engaging REMGs in cancer research requires both institutional- and community-based strategies. This work
identiﬁes practices in the areas of leadership commitment,
standards, and patient- and community-centered practices
that characterize centers of excellence with respect to
recruiting REMGs to cancer clinical trials. Major ﬁndings
were captured in pre- and postinterview surveys and expanded on during all leader interviews. In particular, these
centers achieved sustainable high recruitment of REMGs
by excelling in:
1. Strategic engagement with providers, as they are the
most important inﬂuence on whether the patient is
recruited and participates in clinical trials
2. Community leader engagement as a core center
function which results in trust and engagement with
REMGs and their care partners

3. Seeking dedicated input into cancer clinical research
programs, such as feasibility of implementation, from
REMG patients and caregivers.
4. Establishing clear, cross–cancer center leadership
commitment to quality and hiring practices to ensure
that the composition of research staff represents the
population served, allied with a corresponding development and training culture
Leading centers demonstrate an early focus and long-term
commitment to physician training and cancer research. At
FCCC, fellows, residents, and medical staff receive cultural
competence training, learning about how religion and health
literacy, for example, affect the patient experience and
participation in research. Several cancer centers, including
MUSC, have long-standing research and training programs
that are afﬁliated with minority-serving institutions that train
future researchers and providers in health disparities.21
Similarly, the Asian American Network for Cancer Awareness Research and Training enables a mentoring research
culture in which junior faculty at UCDCCC focus on disparities and the importance of health equity in research.22
An example of how to develop a sustainable, 20-year cancer
disparity research culture is from JVCI, which includes a
collaborative approach with the community and perseverance.23 JVCI has fostered trust among the American Indian
tribal communities with frequent trips, listening, and hiring of
American Indian staff from the local communities. Together
with research center staff, they have developed successful
interventions to increase REMG recruitment to cancer trials
by demonstrating cultural competency and authentically
meeting the needs of the community.24
A recent American Cancer Society report1 supports center
of excellence practices. Complementary recommendations
from this report include the following: seek engagement
and partnerships with community leaders and communitybased organizations, especially those serving REMGs as
well as medically underserved communities, to effectively
disseminate information about the importance of clinical
research participation as a social justice issue; present
patients with cancer with speciﬁcally identiﬁed trial options
as part of the physician–patient treatment decision discussion; design patient-centric trials by using patient input
during the design and implementation phases; select research sites for multisite trials with diverse patient populations that reﬂect the broader population with cancer;
and provide clinical trial navigation services tailored to
REMGs.
It is important to note the limitations that may affect the
interpretation of this cross–cancer center assessment. The
small sample size may have had an impact on the results
reported. Inclusion of additional center types, such as
government facilities, independent cancer centers, different health care systems, and additional geographies, may
have yielded different ﬁndings. Six of the eight centers were
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National Cancer Institute-designated cancer centers. This
could lead to the suggestion that the notable practices
identiﬁed are not generalizable or transferable to other US
centers because of the level of longstanding National Institutes of Health funding that may allow for capacity
building. However, low-cost resource strategies for improved REMG recruitment were recommended by center
leaders during interviews. There was no comparison group
of like centers in similar geographies with low accrual rates
to fully determine and validate the center-reported drivers
of success and there was no priority assessment of drivers
of success.
While acknowledging the potential limitations of the current
report, we encourage cancer center leaders to transparently share and publish approaches and continue to
learn from others in the ﬁeld of diversity and inclusion in
cancer research. We suggest that, if, as a result of this
assessment and report, all the drivers of success for accrual
of REMGs are optimized, it may result in a general trend
toward the improvement of accrual rates of diverse populations beyond the current cancer center sample. The
hope is that REMG inclusion becomes a routine part of
cancer research center activity as a core capability. Engagement of REMGs in nonclinical studies, as well as
models of community health assessments and community
partner models, are areas worthy of additional exploration
as part of an overall cancer center strategy.
CWG industry members’ organizations report that they are
actively working to establish practices in support or recruitment and retention of REMGs in cancer clinical
trials.25-29 These include:
1. Proactive identiﬁcation of new trial sites during the
selection process to understand their approach and
capabilities, asking active investigator sites to recruit a
diverse patient cohort and provide their recruitment
strategy

2. Careful consideration of protocol inclusions and exclusions, such as non–clinically relevant criteria that
disproportionately affect REMGs
3. Discussion of prospective support/logistics measures
for patients so that patients understand what is
available to them in the recruiting stage
4. During investigator meetings, provide a rationale for
the inclusion of REMGs and provide sites that are
culturally sensitive and health literate recruitment
materials for use by research staff
5. Active engagement by industry-supported patient
engagement programs of representative populations of
patients and care partners for insights into protocol
and feasibility designs
6. Working with patient organizations to share and educate membership about the availability of speciﬁc
clinical studies
The advent of promising novel therapies, including immunotherapy and recently discovered genetic therapies,
create urgency to improve clinical trial enrollment of
REMGs and advance the ﬁeld. It is critical that REMGs and
those who are at higher risk of disease or with poor
prognosis participate in genetic testing and clinical research programs in cancer trials and other disease areas if
we are to achieve beneﬁt for the whole population.30,31 In
conclusion, we have identiﬁed leadership, patient engagement, and community engagement practices that
facilitate increased accrual of REMGs in cancer trials. To
establish a sustainable cancer center inclusion research
strategy, it is valuable to consider capabilities and practices
that are informed by leading US cancer centers. Continued
focus and progress on increased participation of REMGs in
cancer research is needed from multiple collaborative
stakeholders to continue to improve our understanding
of differences in risk and disease outcomes across
populations.
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